Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 5, 2008, Pages 720-725

  Van Der Krabben, M D ^a   Rosendaal, Fritzs R ^a   Van Der Bom, J G ^a   Doggen, C J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Coagulation factor; Epidemiology; Polymorphism

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN;

ADULT; ANTICOAGULATION; ARTICLE; DNA DETERMINATION; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; BLOOD COAGULATION FACTORS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FIBRINOGEN; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RECURRENCE; RISK FACTORS;

EID: 42149120675     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02930.x     Document Type: Article

References (35)

1. Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
2. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res 1993; 70: 1-38.
3. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
4. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
5. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA 2005; 294: 1799-809.
6. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
7. Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, Wilson PF, Muller JE, D'Agostino RB Sr. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000; 102: 1634-8.
8. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
9. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
10. Durante-Mangoni E, Davies GJ, Ahmed N, Ruggiero G, Michaelides K. The prothrombin G20210A polymorphism in patients with myocardial infarction. Blood Coagul Fibrinolysis 2002; 13: 603-8.
11. Doggen CJM, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-5.
12. van der Bom JG, De Maat MP, Bots ML, Haverkate F, de Jong PT, Hofman A, Kluft C, Grobbee DE. Elevated plasma fibrinogen: Cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol 1998; 18: 621-5.
13. Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: Results from the Cardiovascular Health Study. Thromb Haemost 2002; 87: 614-21.
14. Doggen CJM, Bertina RM, Manger Cats V, Rosendaal FR. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 2000; 110: 935-8.
15. Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, Delepine M, Lathrop M, Peto R, Collins R. Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'. Int J Epidemiol 2006; 35: 935-43.
16. Davey Smith G, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 2005; 330: 1076-9.
17. Burzotta F, Paciaroni K, De Stefano V, Crea F, Maseri A, Leone G, Andreotti F. G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: A phenotype-specific meta-analysis of 12 034 subjects. Heart 2004; 90: 82-6.
18. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-8.
19. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A systematic review. Circulation 2001; 104: 3063-8.
20. Zee RY, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Ridker PM. Multi-locus candidate gene polymorphisms and risk of myocardial infarction: A population-based, prospective genetic analysis. J Thromb Haemost 2006; 4: 341-8.
21. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM Jr, Arora R, Marcus FI, et.al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 2517-22.
22. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20: 2019-23.
23. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
24. Green F, Hamsten A, Blomback M, Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-20.
25. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; 1: 1452-5.
26. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005; 149: 606-12.
27. Doggen CJM, Manger Cats V, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
28. Middendorf K, Gohring P, Huehns TY, Seidel D, Steinbeck G, Nikol S. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction. Am Heart J 2004; 147: 897-904.
29. Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Benedetta DM. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
30. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, Mazzucco A, Bernardi F, Corrocher R. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343: 774-80.
31. Iwai N, Shimoike H, Nakamura Y, Tamaki S, Kinoshita M. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 1998; 136: 109-14.
32. Mikkelsson J, Perola M, Wartiovaara U, Peltonen L, Palotie A, Penttila A, Karhunen PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. Thromb Haemost 2000; 84: 78-82.
33. Moss AJ, Ryan D, Oakes D, Goldstein RE, Greenberg H, Bodenheimer MM, Brown MW, Case RB, Dwyer EM Jr, Eberly SW, Francis CW, Gillespie JA, Krone RJ, Lichstein E, MacCluer JW, Marcus FI, McCarthy J, Sparks CE, Zareba W. Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction. Am J Cardiol 2005; 96: 177-82.
34. Burzotta F, Leone AM, Paciaroni K, De Stefano V, Rossi E, Testa L, Giannico F, Leone G, Maseri A, Crea F, Andreotti F. G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. Haematologica 2004; 89: 1134-8.
35. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-50.